Compugen (CGEN) has released an update. Compugen Ltd. has secured a new U.S. patent for its innovative cancer treatment approach, involving the combination of its COM902 antibody with anti-PD-1 and
Compugen (CGEN) has released an update. Compugen Ltd. has secured a new U.S. patent for its innovative cancer treatment approach, involving the combination of its COM902 antibody with anti-PD-1 and
Compugen (CGEN) announced that the United States Patent and Trademark Office has granted the company a new patent covering method of use for COM902, the company’s potential best-in-class reduced Fc,
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Compugen (CGEN – Research Report). The company’s shares closed yesterday at $1.60. Goonewardene covers the
Compugen ( ($CGEN) ) has released its Q3 earnings. Here is a breakdown of the information Compugen presented to its investors. Compugen Ltd. is a clinical-stage cancer immunotherapy company, pioneering
Compugen (CGEN) has released an update. Compugen reported strong third-quarter financial results for 2024, with a net profit of $1.3 million, a significant improvement from the previous year’s loss. The